Condition: Plasma Cell Myeloma Refractory · Sponsor: Sanofi
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona - Phoenix- Site Number : 8400058 | Phoenix, Arizona, United States | Recruiting |
| Los Angeles Hematology Oncology Medical Group- Site Number : 8400027 | Los Angeles, California, United States | Recruiting |
| Private Practice - Dr. James R. Berenson- Site Number : 8400044 | West Hollywood, California, United States | Recruiting |
| Smilow Cancer Center at Yale-New Haven- Site Number : 8400020 | New Haven, Connecticut, United States | Recruiting |
| Maryland Oncology Hematology- Site Number : 8400038 | Washington D.C., District of Columbia, United States | Recruiting |
| Life Clinical Trials - Coral Springs- Site Number : 8400055 | Coral Springs, Florida, United States | Recruiting |
| Center for Rheumatology, Immunology and Arthritis- Site Number : 8400031 | Fort Lauderdale, Florida, United States | Recruiting |
| Mayo Clinic in Florida- Site Number : 8400002 | Jacksonville, Florida, United States | Recruiting |
| The Oncology Institute of Hope & Innovation - Lakeland- Site Number : 8400054 | Lakeland, Florida, United States | Recruiting |
| D&H Pompano Research Center- Site Number : 8400049 | Margate, Florida, United States | Recruiting |
| Millennium Oncology - Pembroke Pines- Site Number : 8400011 | Pembroke Pines, Florida, United States | Recruiting |
| BRCR Global- Site Number : 8400008 | Plantation, Florida, United States | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06356571